Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The expanded GAA repeat in the frataxin gene is a large trinucleotide (GAA) repeat expansion mutation occurring in intron 1 of the FXN gene. In healthy individuals, this repeat is usually fewer than 12–33 units, while in individuals with Friedreich’s ataxia, the repeat expands to 66 up to >1,000 units. This expansion causes gene silencing through heterochromatin formation and other repressive epigenetic mechanisms, leading to severely reduced frataxin expression. Frataxin is essential for mitochondrial function; its deficiency results in neurodegeneration, most prominently manifesting as Friedreich’s ataxia. The expanded repeat does not encode a protein or act as a receptor, enzyme, or transporter, but directly causes disease by pathologically altering gene expression and chromatin state.
Epigenetic modulation: HDAC inhibitors and other agents aim to reverse repeat-induced silencing by promoting chromatin relaxation and restoring frataxin expression.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Expanded GAA trinucleotide repeat in the frataxin gene.